Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) COO Sells $196,854.00 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 10,900 shares of the firm’s stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $18.06, for a total value of $196,854.00. Following the transaction, the chief operating officer owned 202,641 shares of the company’s stock, valued at approximately $3,659,696.46. This represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Ryan Cohlhepp also recently made the following trade(s):

• On Monday, October 6th, Ryan Cohlhepp sold 39,600 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.06, for a total value of $715,176.00.

Bicara Therapeutics Stock Down 2.6%

BCAX opened at $17.78 on Friday. Bicara Therapeutics Inc. has a 52 week low of $7.80 and a 52 week high of $28.09. The business has a fifty day simple moving average of $12.51 and a 200-day simple moving average of $11.87. The firm has a market cap of $970.97 million and a P/E ratio of -5.61.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.04. Sell-side analysts expect that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Institutional Investors Weigh In On Bicara Therapeutics

Institutional investors have recently modified their holdings of the company. California State Teachers Retirement System purchased a new stake in shares of Bicara Therapeutics during the 4th quarter worth $25,000. CWM LLC acquired a new stake in shares of Bicara Therapeutics during the 1st quarter worth about $29,000. Legal & General Group Plc raised its position in shares of Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Bicara Therapeutics by 73.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after acquiring an additional 1,474 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after acquiring an additional 3,866 shares in the last quarter.

Analyst Ratings Changes

BCAX has been the topic of several research reports. HC Wainwright reduced their price target on shares of Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, August 22nd. Piper Sandler assumed coverage on Bicara Therapeutics in a research report on Monday, August 18th. They set an “overweight” rating and a $36.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicara Therapeutics in a research report on Saturday, September 27th. Finally, Wedbush reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.86.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.